All In MedTech

PMA device

Biofinity (Confilcon A) Soft Contact Lenses

Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed

FDA decisions

4

PMA pathway

Device trials

63

Naming "Biofinity"

MAUDE reports

506

Brand "Biofinity", since 2015

PubMed studies

59

Mentioning "Biofinity"

AI summary across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.

Product review deck

A slide deck reviewing Biofinity (Confilcon A) Soft Contact Lenses

About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.

  • Executive summary and key facts
  • Technology
  • Clinical evidence and trials
  • Regulatory history and safety
  • Reimbursement, market and competition
  • Risks, outlook and sources

AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.

FDA decisions

The newest 4 of 4 decisions filed under this name.

1 more FDA decisions with a free account

Medicare coverage

National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.

How devices get paid for

Clinical trials

Device studies on ClinicalTrials.gov that name "Biofinity", any status and sponsor, newest update first.

Open in Trial Radar
  • Ohio State UniversityAcademic, hospital or other

    NCT06064617 · 20 participants · Start Nov 1, 2023 · Primary completion Apr 30, 2024

    Device: Center-Near (+2.50D) Coopervision Biofinity Multifocal Contact Lens; Center Distance (+2.50 D) Coopervision Biofinity Multifocal Contact Lens · For: Accommodation Disorder

    Sites: Columbus, Ohio

  • CooperVision, Inc.Not on our public-company list

    NCT06431061 · 37 participants · Start Jun 4, 2024 · Primary completion Nov 13, 2024

    Device: Lens A (omafilcon B); Lens B (comfilcon A) · For: Astigmatism

    Sites: Waterloo, Canada

  • Alcon ResearchNot on our public-company list

    NCT05886881 · 505 participants · Start Aug 3, 2023 · Primary completion Apr 15, 2025

    Device: Lotrafilcon B spherical soft contact lenses; Lotrafilcon B spherical soft contact lenses with comfort additive and 3 more · For: Refractive Errors

    Sites: Orlando, Florida; Medina, Minnesota; St Louis, Missouri · 4 sites in all

60 more trials with a free account

Adverse event reports (MAUDE)

Reports received since 2015 naming the brand "Biofinity", and for the whole product code for context.

This brand

506 reports: 5 malfunction, 498 injury, 0 death

Whole product code LPM

1,788 reports: 19 malfunction, 1,759 injury, 0 death

Newest reports for this brand

2 more reports with a free account

All reports in MAUDE Monitor

Recalls

From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.

1 more recall records with a free account

Published research

The most relevant PubMed records for "Biofinity"[tiab]. The summary above synthesizes these.

PubMedGoogle ScholarLiterature search

Other devices of this type

Also filed under product code LPM.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.